PCSA — Processa Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Processa Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Processa Pharmaceuticals Inc expected to post a loss of $1.18 a share - Earnings Preview
Processa Pharmaceuticals Inc expected to post a loss of $1.60 a share - Earnings Preview
Brief: Processa Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Rule
Brief: Processa Pharmaceuticals Announces Pricing Of $7.0 Million Public Offering
U.S. STOCKS ON THE MOVE-Humana, Boeing, Tesla
U.S. STOCKS ON THE MOVE-ResMed, United Rentals, McCormick
Processa Pharma rises as cancer treatment shows promise in early-stage study
Processa Pharma rises as cancer treatment shows promise in early-stage study
Brief: Processa Pharmaceuticals Announces Successful Completion Of Phase 1B Safety Evaluation Of NGC-Cap
U.S. STOCKS ON THE MOVE-Fisker, Best Buy, NuStar Energy
U.S. STOCKS ON THE MOVE-SciSparc, Teekay Tankers
U.S. STOCKS ON THE MOVE-Intuitive Surgical, Ally Financial, Modular Medical
U.S. STOCKS ON THE MOVE-IBM, Wayfair, Netflix
Processa soars on expanding into breast cancer treatment trial
Brief: Processa Pharmaceuticals Reverse Stock Split Intended To Regain Compliance With Minimum Bid Price Requirement And Continued Listing On Nasdaq
Brief: Processa Pharmaceuticals Provides Interim Analysis From Ongoing Phase 1B Trial Of Next Generation Capecitabine Showing Improved Safety Over Capecitabine
Brief: Processa Pharmaceuticals Announces Successful Phase 2 Meeting With FDA For Next Generation Capecitabine
Brief: Processa Pharma Issues Letter To Shareholders Highlighting Corporate Strategy, Drug Pipeline & Outlook